Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?

Background. Several African countries have adopted a biannual ivermectin distribution strategy in some foci to control and eliminate onchocerciasis. In 2010, the Ghana Health Service started biannual distribution to combat transmission hotspots and suboptimal responses to treatment. We assessed the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2016-06, Vol.62 (11), p.1338-1347
Hauptverfasser: Frempong, Kwadwo K., Walker, Martin, Cheke, Robert A., Tetevi, Edward Jenner, Gyan, Ernest Tawiah, Owusu, Ebenezer O., Wilson, Michael D., Boakye, Daniel A., Taylor, Mark J., Biritwum, Nana-Kwadwo, Osei-Atweneboana, Mike, Basáñez, María-Gloria
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1347
container_issue 11
container_start_page 1338
container_title Clinical infectious diseases
container_volume 62
creator Frempong, Kwadwo K.
Walker, Martin
Cheke, Robert A.
Tetevi, Edward Jenner
Gyan, Ernest Tawiah
Owusu, Ebenezer O.
Wilson, Michael D.
Boakye, Daniel A.
Taylor, Mark J.
Biritwum, Nana-Kwadwo
Osei-Atweneboana, Mike
Basáñez, María-Gloria
description Background. Several African countries have adopted a biannual ivermectin distribution strategy in some foci to control and eliminate onchocerciasis. In 2010, the Ghana Health Service started biannual distribution to combat transmission hotspots and suboptimal responses to treatment. We assessed the epidemiological impact of the first 3 years of this strategy and quantified responses to ivermectin over 2 consecutive rounds of treatment in 10 sentinel communities. Methods. We evaluated Onchocerca volvulus community microfilarial intensity and prevalence in persons aged ≥20 years before the first, second, and fifth (or sixth) biannual treatment rounds using skin snip data from 956 participants. We used longitudinal regression modeling to estimate rates of microfilarial repopulation of the skin in a cohort of 217 participants who were followed up over the first 2 rounds of biannual treatment. Results. Biannual treatment has had a positive impact, with substantial reductions in infection intensity after 4 or 5 rounds in most communities. We identified 3 communities—all having been previously recognized as responding suboptimally to ivermectin—with statistically significantly high microfilarial repopulation rates. We did not find any clear association between microfilarial repopulation rate and the number of years of prior intervention, coverage, or the community level of infection. Conclusions. The strategy of biannual ivermectin treatment in Ghana has reduced O. volvulus microfilarial intensity and prevalence, but suboptimal responses to treatment remain evident in a number of previously and consistently implicated communities. Whether increasing the frequency of treatment will be sufficient to meet the World Health Organization's 2020 elimination goals remains uncertain.
doi_str_mv 10.1093/cid/ciw144
format Article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4872292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26370994</jstor_id><sourcerecordid>26370994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c461t-be750858757fe00e84cf949d046095498d58c884bba8baa0e56778b403cf9e9d3</originalsourceid><addsrcrecordid>eNqFks1vFSEUxYnR2FrduNeQuGmaTIUZGGCjaZ-tfUkTk1rXhGHutLzMwCswNd36l8vrq_Vj44JwkvvjhHvvQeg1JYeUqOa9dX053yljT9Au5Y2oWq7o06IJlxWTjdxBL1JaEUKpJPw52qlF0ZLQXfTjU4CEl95GMMn5K3xZRJ7AZ3wa4WYGb-_wUd9HSAl_nbuwzm4yI76AtA4-lbc54OUtxAlsdh4PIeJ8DXgRfI5hxMb3-GR0k_Mmu-BxGPCFKzg-Hp3vfXH9-BI9G8yY4NXDvYe-nZ5cLs6q8y-fl4uj88qyluaqA8GJ5FJwMQAhIJkdFFM9YS1RnCnZc2mlZF1nZGcMAd4KITtGmsKB6ps99GHru567CXpbeoxm1OtYGop3Ohin_654d62vwq1mUtS1qovB_oNBDGUyKevJJQvjaDyEOekyUdm2jarJ_1GhNhuQqi3ou3_QVZijL5PYUE1bc3JveLClbAwpRRge_02J3qRAlxTobQoK_PbPTh_RX2svwJstsEo5xN_1thFEKdb8BJ_jubc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1793625020</pqid></control><display><type>article</type><title>Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Frempong, Kwadwo K. ; Walker, Martin ; Cheke, Robert A. ; Tetevi, Edward Jenner ; Gyan, Ernest Tawiah ; Owusu, Ebenezer O. ; Wilson, Michael D. ; Boakye, Daniel A. ; Taylor, Mark J. ; Biritwum, Nana-Kwadwo ; Osei-Atweneboana, Mike ; Basáñez, María-Gloria</creator><creatorcontrib>Frempong, Kwadwo K. ; Walker, Martin ; Cheke, Robert A. ; Tetevi, Edward Jenner ; Gyan, Ernest Tawiah ; Owusu, Ebenezer O. ; Wilson, Michael D. ; Boakye, Daniel A. ; Taylor, Mark J. ; Biritwum, Nana-Kwadwo ; Osei-Atweneboana, Mike ; Basáñez, María-Gloria</creatorcontrib><description>Background. Several African countries have adopted a biannual ivermectin distribution strategy in some foci to control and eliminate onchocerciasis. In 2010, the Ghana Health Service started biannual distribution to combat transmission hotspots and suboptimal responses to treatment. We assessed the epidemiological impact of the first 3 years of this strategy and quantified responses to ivermectin over 2 consecutive rounds of treatment in 10 sentinel communities. Methods. We evaluated Onchocerca volvulus community microfilarial intensity and prevalence in persons aged ≥20 years before the first, second, and fifth (or sixth) biannual treatment rounds using skin snip data from 956 participants. We used longitudinal regression modeling to estimate rates of microfilarial repopulation of the skin in a cohort of 217 participants who were followed up over the first 2 rounds of biannual treatment. Results. Biannual treatment has had a positive impact, with substantial reductions in infection intensity after 4 or 5 rounds in most communities. We identified 3 communities—all having been previously recognized as responding suboptimally to ivermectin—with statistically significantly high microfilarial repopulation rates. We did not find any clear association between microfilarial repopulation rate and the number of years of prior intervention, coverage, or the community level of infection. Conclusions. The strategy of biannual ivermectin treatment in Ghana has reduced O. volvulus microfilarial intensity and prevalence, but suboptimal responses to treatment remain evident in a number of previously and consistently implicated communities. Whether increasing the frequency of treatment will be sufficient to meet the World Health Organization's 2020 elimination goals remains uncertain.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciw144</identifier><identifier>PMID: 27001801</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Adult ; and Commentaries ; Antiparasitic Agents - administration &amp; dosage ; Antiparasitic Agents - therapeutic use ; ARTICLES AND COMMENTARIES ; Cohort Studies ; Epidemiology ; Ghana - epidemiology ; Humans ; Ivermectin - administration &amp; dosage ; Ivermectin - therapeutic use ; Male ; Medical treatment ; Onchocerca volvulus ; Onchocerciasis, Ocular - drug therapy ; Onchocerciasis, Ocular - epidemiology ; Onchocerciasis, Ocular - parasitology ; Parasite Load ; Parasitic diseases ; Prescription drugs ; Prevalence ; Skin - parasitology ; Treatment Outcome ; Young Adult</subject><ispartof>Clinical infectious diseases, 2016-06, Vol.62 (11), p.1338-1347</ispartof><rights>Copyright © 2016 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.</rights><rights>Copyright Oxford University Press, UK Jun 1, 2016</rights><rights>The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c461t-be750858757fe00e84cf949d046095498d58c884bba8baa0e56778b403cf9e9d3</citedby><cites>FETCH-LOGICAL-c461t-be750858757fe00e84cf949d046095498d58c884bba8baa0e56778b403cf9e9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26370994$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26370994$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,799,881,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27001801$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frempong, Kwadwo K.</creatorcontrib><creatorcontrib>Walker, Martin</creatorcontrib><creatorcontrib>Cheke, Robert A.</creatorcontrib><creatorcontrib>Tetevi, Edward Jenner</creatorcontrib><creatorcontrib>Gyan, Ernest Tawiah</creatorcontrib><creatorcontrib>Owusu, Ebenezer O.</creatorcontrib><creatorcontrib>Wilson, Michael D.</creatorcontrib><creatorcontrib>Boakye, Daniel A.</creatorcontrib><creatorcontrib>Taylor, Mark J.</creatorcontrib><creatorcontrib>Biritwum, Nana-Kwadwo</creatorcontrib><creatorcontrib>Osei-Atweneboana, Mike</creatorcontrib><creatorcontrib>Basáñez, María-Gloria</creatorcontrib><title>Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Background. Several African countries have adopted a biannual ivermectin distribution strategy in some foci to control and eliminate onchocerciasis. In 2010, the Ghana Health Service started biannual distribution to combat transmission hotspots and suboptimal responses to treatment. We assessed the epidemiological impact of the first 3 years of this strategy and quantified responses to ivermectin over 2 consecutive rounds of treatment in 10 sentinel communities. Methods. We evaluated Onchocerca volvulus community microfilarial intensity and prevalence in persons aged ≥20 years before the first, second, and fifth (or sixth) biannual treatment rounds using skin snip data from 956 participants. We used longitudinal regression modeling to estimate rates of microfilarial repopulation of the skin in a cohort of 217 participants who were followed up over the first 2 rounds of biannual treatment. Results. Biannual treatment has had a positive impact, with substantial reductions in infection intensity after 4 or 5 rounds in most communities. We identified 3 communities—all having been previously recognized as responding suboptimally to ivermectin—with statistically significantly high microfilarial repopulation rates. We did not find any clear association between microfilarial repopulation rate and the number of years of prior intervention, coverage, or the community level of infection. Conclusions. The strategy of biannual ivermectin treatment in Ghana has reduced O. volvulus microfilarial intensity and prevalence, but suboptimal responses to treatment remain evident in a number of previously and consistently implicated communities. Whether increasing the frequency of treatment will be sufficient to meet the World Health Organization's 2020 elimination goals remains uncertain.</description><subject>Adult</subject><subject>and Commentaries</subject><subject>Antiparasitic Agents - administration &amp; dosage</subject><subject>Antiparasitic Agents - therapeutic use</subject><subject>ARTICLES AND COMMENTARIES</subject><subject>Cohort Studies</subject><subject>Epidemiology</subject><subject>Ghana - epidemiology</subject><subject>Humans</subject><subject>Ivermectin - administration &amp; dosage</subject><subject>Ivermectin - therapeutic use</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Onchocerca volvulus</subject><subject>Onchocerciasis, Ocular - drug therapy</subject><subject>Onchocerciasis, Ocular - epidemiology</subject><subject>Onchocerciasis, Ocular - parasitology</subject><subject>Parasite Load</subject><subject>Parasitic diseases</subject><subject>Prescription drugs</subject><subject>Prevalence</subject><subject>Skin - parasitology</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks1vFSEUxYnR2FrduNeQuGmaTIUZGGCjaZ-tfUkTk1rXhGHutLzMwCswNd36l8vrq_Vj44JwkvvjhHvvQeg1JYeUqOa9dX053yljT9Au5Y2oWq7o06IJlxWTjdxBL1JaEUKpJPw52qlF0ZLQXfTjU4CEl95GMMn5K3xZRJ7AZ3wa4WYGb-_wUd9HSAl_nbuwzm4yI76AtA4-lbc54OUtxAlsdh4PIeJ8DXgRfI5hxMb3-GR0k_Mmu-BxGPCFKzg-Hp3vfXH9-BI9G8yY4NXDvYe-nZ5cLs6q8y-fl4uj88qyluaqA8GJ5FJwMQAhIJkdFFM9YS1RnCnZc2mlZF1nZGcMAd4KITtGmsKB6ps99GHru567CXpbeoxm1OtYGop3Ohin_654d62vwq1mUtS1qovB_oNBDGUyKevJJQvjaDyEOekyUdm2jarJ_1GhNhuQqi3ou3_QVZijL5PYUE1bc3JveLClbAwpRRge_02J3qRAlxTobQoK_PbPTh_RX2svwJstsEo5xN_1thFEKdb8BJ_jubc</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Frempong, Kwadwo K.</creator><creator>Walker, Martin</creator><creator>Cheke, Robert A.</creator><creator>Tetevi, Edward Jenner</creator><creator>Gyan, Ernest Tawiah</creator><creator>Owusu, Ebenezer O.</creator><creator>Wilson, Michael D.</creator><creator>Boakye, Daniel A.</creator><creator>Taylor, Mark J.</creator><creator>Biritwum, Nana-Kwadwo</creator><creator>Osei-Atweneboana, Mike</creator><creator>Basáñez, María-Gloria</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>7U2</scope><scope>5PM</scope></search><sort><creationdate>20160601</creationdate><title>Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?</title><author>Frempong, Kwadwo K. ; Walker, Martin ; Cheke, Robert A. ; Tetevi, Edward Jenner ; Gyan, Ernest Tawiah ; Owusu, Ebenezer O. ; Wilson, Michael D. ; Boakye, Daniel A. ; Taylor, Mark J. ; Biritwum, Nana-Kwadwo ; Osei-Atweneboana, Mike ; Basáñez, María-Gloria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c461t-be750858757fe00e84cf949d046095498d58c884bba8baa0e56778b403cf9e9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>and Commentaries</topic><topic>Antiparasitic Agents - administration &amp; dosage</topic><topic>Antiparasitic Agents - therapeutic use</topic><topic>ARTICLES AND COMMENTARIES</topic><topic>Cohort Studies</topic><topic>Epidemiology</topic><topic>Ghana - epidemiology</topic><topic>Humans</topic><topic>Ivermectin - administration &amp; dosage</topic><topic>Ivermectin - therapeutic use</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Onchocerca volvulus</topic><topic>Onchocerciasis, Ocular - drug therapy</topic><topic>Onchocerciasis, Ocular - epidemiology</topic><topic>Onchocerciasis, Ocular - parasitology</topic><topic>Parasite Load</topic><topic>Parasitic diseases</topic><topic>Prescription drugs</topic><topic>Prevalence</topic><topic>Skin - parasitology</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frempong, Kwadwo K.</creatorcontrib><creatorcontrib>Walker, Martin</creatorcontrib><creatorcontrib>Cheke, Robert A.</creatorcontrib><creatorcontrib>Tetevi, Edward Jenner</creatorcontrib><creatorcontrib>Gyan, Ernest Tawiah</creatorcontrib><creatorcontrib>Owusu, Ebenezer O.</creatorcontrib><creatorcontrib>Wilson, Michael D.</creatorcontrib><creatorcontrib>Boakye, Daniel A.</creatorcontrib><creatorcontrib>Taylor, Mark J.</creatorcontrib><creatorcontrib>Biritwum, Nana-Kwadwo</creatorcontrib><creatorcontrib>Osei-Atweneboana, Mike</creatorcontrib><creatorcontrib>Basáñez, María-Gloria</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frempong, Kwadwo K.</au><au>Walker, Martin</au><au>Cheke, Robert A.</au><au>Tetevi, Edward Jenner</au><au>Gyan, Ernest Tawiah</au><au>Owusu, Ebenezer O.</au><au>Wilson, Michael D.</au><au>Boakye, Daniel A.</au><au>Taylor, Mark J.</au><au>Biritwum, Nana-Kwadwo</au><au>Osei-Atweneboana, Mike</au><au>Basáñez, María-Gloria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>62</volume><issue>11</issue><spage>1338</spage><epage>1347</epage><pages>1338-1347</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Background. Several African countries have adopted a biannual ivermectin distribution strategy in some foci to control and eliminate onchocerciasis. In 2010, the Ghana Health Service started biannual distribution to combat transmission hotspots and suboptimal responses to treatment. We assessed the epidemiological impact of the first 3 years of this strategy and quantified responses to ivermectin over 2 consecutive rounds of treatment in 10 sentinel communities. Methods. We evaluated Onchocerca volvulus community microfilarial intensity and prevalence in persons aged ≥20 years before the first, second, and fifth (or sixth) biannual treatment rounds using skin snip data from 956 participants. We used longitudinal regression modeling to estimate rates of microfilarial repopulation of the skin in a cohort of 217 participants who were followed up over the first 2 rounds of biannual treatment. Results. Biannual treatment has had a positive impact, with substantial reductions in infection intensity after 4 or 5 rounds in most communities. We identified 3 communities—all having been previously recognized as responding suboptimally to ivermectin—with statistically significantly high microfilarial repopulation rates. We did not find any clear association between microfilarial repopulation rate and the number of years of prior intervention, coverage, or the community level of infection. Conclusions. The strategy of biannual ivermectin treatment in Ghana has reduced O. volvulus microfilarial intensity and prevalence, but suboptimal responses to treatment remain evident in a number of previously and consistently implicated communities. Whether increasing the frequency of treatment will be sufficient to meet the World Health Organization's 2020 elimination goals remains uncertain.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>27001801</pmid><doi>10.1093/cid/ciw144</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2016-06, Vol.62 (11), p.1338-1347
issn 1058-4838
1537-6591
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4872292
source Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adult
and Commentaries
Antiparasitic Agents - administration & dosage
Antiparasitic Agents - therapeutic use
ARTICLES AND COMMENTARIES
Cohort Studies
Epidemiology
Ghana - epidemiology
Humans
Ivermectin - administration & dosage
Ivermectin - therapeutic use
Male
Medical treatment
Onchocerca volvulus
Onchocerciasis, Ocular - drug therapy
Onchocerciasis, Ocular - epidemiology
Onchocerciasis, Ocular - parasitology
Parasite Load
Parasitic diseases
Prescription drugs
Prevalence
Skin - parasitology
Treatment Outcome
Young Adult
title Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T09%3A05%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20Increasing%20Treatment%20Frequency%20Address%20Suboptimal%20Responses%20to%20Ivermectin%20for%20the%20Control%20and%20Elimination%20of%20River%20Blindness?&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Frempong,%20Kwadwo%20K.&rft.date=2016-06-01&rft.volume=62&rft.issue=11&rft.spage=1338&rft.epage=1347&rft.pages=1338-1347&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciw144&rft_dat=%3Cjstor_pubme%3E26370994%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1793625020&rft_id=info:pmid/27001801&rft_jstor_id=26370994&rfr_iscdi=true